{"id":296,"date":"2020-06-22T06:39:36","date_gmt":"2020-06-22T06:39:36","guid":{"rendered":"https:\/\/nclinnovations.org\/covid19monitor\/?p=296"},"modified":"2020-06-22T06:40:32","modified_gmt":"2020-06-22T06:40:32","slug":"22-june-2020-hydroxychloroquine-no-significant-reduction-of-the-risk-of-unfavorable-outcomes","status":"publish","type":"post","link":"https:\/\/nclinnovations.org\/covid19monitor\/22-june-2020-hydroxychloroquine-no-significant-reduction-of-the-risk-of-unfavorable-outcomes\/","title":{"rendered":"(22 June 2020) Hydroxychloroquine- no significant reduction of the risk of unfavorable outcomes"},"content":{"rendered":"<div class=\"boldgrid-section\">\n<div class=\"container\">\n<div class=\"row\">\n<div class=\"col-md-12 col-xs-12 col-sm-12\">\n<p class=\"\">Compassionate use of hydroxychloroquine in clinical practice for patients with mild to severe Covid-19 in a French university hospital<\/p>\n<p>https:\/\/www.ncbi.nlm.nih.gov\/research\/coronavirus\/publication\/32556143<\/p>\n<p class=\"\">In an observational, retrospective cohort study involving hospitalized adult patients with confirmed, mild to severe Covid-19 in a French university hospital, patients who received hydroxychloroquine (200mg tid dosage for 10 days) on a compassionate basis in addition to SOCwere compared to patients without contraindications to hydroxychloroquine who received SOCalone were compared. The primary endpoint was time to unfavorable outcome, defined as: death, admission to an intensive care unit, or decision to withdraw or withhold life-sustaining treatments, whichever came first. Data from 89 patients with laboratory-confirmed Covid-19 were analyzed, 84 of whom were considered in the primary analysis; 38 patients treated with hydroxychloroquine and 46 patients treated with SOCalone. After propensity score weighting, treatment with hydroxycholoroquine was not associated with a significantly reduced risk of unfavorable outcome (HR 0.90 [0.38; 2.1], p = 0.81). Overall survival was not significantly different between the two groups (HR 0.89 [0.23; 3.47], p = 1).&nbsp; In hospitalized adults with Covid-19, no significant reduction of the risk of unfavorable outcomes was observed with hydroxychloroquine in comparison to standard of care.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Compassionate use of hydroxychloroquine in clinical practice for patients with mild to severe Covid-19 in a French university hospital https:\/\/www.ncbi.nlm.nih.gov\/research\/coronavirus\/publication\/32556143 In an observational, retrospective cohort study involving hospitalized adult patients with confirmed, mild to severe Covid-19 in a French university&hellip; <span class=\"read-more-span\"><a href=\"https:\/\/nclinnovations.org\/covid19monitor\/22-june-2020-hydroxychloroquine-no-significant-reduction-of-the-risk-of-unfavorable-outcomes\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;(22 June 2020) Hydroxychloroquine- no significant reduction of the risk of unfavorable outcomes&#8221;<\/span> <span class=\"genericon genericon-next\"><\/span><\/a><\/span><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"bgseo_title":"","bgseo_description":"","bgseo_robots_index":"index","bgseo_robots_follow":"follow"},"categories":[4,9],"tags":[10],"_links":{"self":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/296"}],"collection":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/comments?post=296"}],"version-history":[{"count":1,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/296\/revisions"}],"predecessor-version":[{"id":297,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/296\/revisions\/297"}],"wp:attachment":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/media?parent=296"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/categories?post=296"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/tags?post=296"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}